Impact of combined therapy inhibiting EGFR and VEGFR pathway in non-small-cell lung cancer on progression-free and overall survival

The effect of combined epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathway inhibitors on progression-free survival (PFS) and overall survival (OS) in patients with non-small cell lung cancer (NSCLC) remains controversial. Our analysis showed that EGFR-TKIs plus anti-VEGF/VEGFR therapy significantly prolong PFS in the second-line treatment of NSCLC patients. EGFR mutation is a promising indication of this combination treatment.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iUKqHk
via IFTTT